Tag:

Ian Read

Latest Headlines

Latest Headlines

Pfizer's Ibrance shines in latest breast cancer study

Pfizer won accelerated approval of Ibrance as a first-line breast cancer treatment in February. Now it says that data in a study of the drug as a second-line treatment was so good that it stopped that study early.

Pfizer CEO thinks buys and swaps, with an eye toward future breakup

Pfizer CEO Ian Read not only isn't done with deals after his Hospira purchase; he's also looking at creative swaps, a la the Novartis-GlaxoSmithKline deals.

UPDATED: Pfizer beefs up on biosimilars with $15B Hospira deal

Pfizer CEO Ian Read is dipping into the pharma giant's big reserve of cash to gobble up Hospira, one of the pioneers in the move to develop biosimilars of blockbuster biologics.

Pfizer CEO: 'No reason' we can't do an inversion deal, Treasury rules or no

Pfizer CEO Ian Read makes no apologies for his interest in working a deal to move his tax home overseas. Despite the U.S. government's attempt to discourage tax inversions--like the one Pfizer would have achieved by buying AstraZeneca--Read says he's not deterred.

Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebid

No news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEO Ian Read's next buyout move was disappointed after Tuesday's second-quarter earnings call with analysts.

15 Highest-Paid Biopharma CEOs of 2013

Long dominated by global behemoths like Johnson & Johnson and Pfizer, this executive-pay ranking now includes almost as many biotechs as pharma companies.

UPDATED: Pfizer to AstraZeneca: Say goodbye to our $120B offer

With the official deadline for any immediate takeover discussions looming on Monday, Pfizer picked up its ball and bat and headed for the lockers, officially calling an end to its odd quest to buy out AstraZeneca.

UPDATED: AstraZeneca slaps down Pfizer's 'final' $119B takeover bid

AstraZeneca Chairman Leif Johansson condemned the tax inversion scheme at the heart of the proposal--along with the cost-cutting that would have followed the megamerger--and confidently chose to gamble the company's future on its new and expanded pipeline.

Parsing Pfizer's deal talk isn't an exercise. It's the tell on AstraZeneca's future

With U.K. lawmakers skeptical of Pfizer's commitment to keep AstraZeneca jobs and AstraZeneca science in the U.K., Pfizer over the weekend released a series of videos focusing on that science--and downplaying the tax benefits CEO Ian Read crowed about so loudly when first confirming his company's trans-Atlantic bid.

British PM wants more Pfizer promises, but pharma's merger vows are fleeting

Reuters reports that British Prime Minister David Cameron is now demanding stronger guarantees that Pfizer's buyout of AstraZeneca won't decimate the country's science community and leave a host of employees jobless.